{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:50:15Z","timestamp":1791841815689,"version":"4.3.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T00:00:00Z","timestamp":1618617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T00:00:00Z","timestamp":1618617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015453","name":"Adamas Pharmaceuticals, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015453","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s40120-021-00246-3","type":"journal-article","created":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T03:26:01Z","timestamp":1618629961000},"page":"307-320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson\u2019s Disease and Dyskinesia"],"prefix":"10.1007","volume":"10","author":[{"given":"Shyamal H.","family":"Mehta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Pahwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M.","family":"Tanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reed","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,17]]},"reference":[{"issue":"11","key":"246_CR1","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/mds.22643","volume":"24","author":"P Barone","year":"2009","unstructured":"Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson\u2019s disease. Mov Disord. 2009;24(11):1641\u20139. https:\/\/doi.org\/10.1002\/mds.22643.","journal-title":"Mov Disord"},{"issue":"10","key":"246_CR2","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.parkreldis.2011.02.018","volume":"17","author":"KR Chaudhuri","year":"2011","unstructured":"Chaudhuri KR, Odin P, Antonini A, Martinez-Martin P. Parkinson\u2019s disease: the non-motor issues. Parkinsonism Relat Disord. 2011;17(10):717\u201323. https:\/\/doi.org\/10.1016\/j.parkreldis.2011.02.018.","journal-title":"Parkinsonism Relat Disord"},{"issue":"10","key":"246_CR3","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1111\/jgs.12458","volume":"61","author":"NJ Weerkamp","year":"2013","unstructured":"Weerkamp NJ, Tissingh G, Poels PJ, Zuidema SU, Munneke M, Koopmans RT, et al. Nonmotor symptoms in nursing home residents with Parkinson\u2019s disease: prevalence and effect on quality of life. J Am Geriatr Soc. 2013;61(10):1714\u201321. https:\/\/doi.org\/10.1111\/jgs.12458.","journal-title":"J Am Geriatr Soc"},{"issue":"7","key":"246_CR4","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/mds.20844","volume":"21","author":"KR Chaudhuri","year":"2006","unstructured":"Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson\u2019s disease: the NMSQuest study. Mov Disord. 2006;21(7):916\u201323. https:\/\/doi.org\/10.1002\/mds.20844.","journal-title":"Mov Disord"},{"issue":"3","key":"246_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S1353-8020(01)00015-3","volume":"8","author":"LM Shulman","year":"2002","unstructured":"Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2002;8(3):193\u20137.","journal-title":"Parkinsonism Relat Disord"},{"issue":"15","key":"246_CR6","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1002\/mds.23394","volume":"25","author":"DA Gallagher","year":"2010","unstructured":"Gallagher DA, Lees AJ, Schrag A. What are the most important nonmotor symptoms in patients with Parkinson\u2019s disease and are we missing them? Mov Disord. 2010;25(15):2493\u2013500. https:\/\/doi.org\/10.1002\/mds.23394.","journal-title":"Mov Disord"},{"issue":"6","key":"246_CR7","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/mds.22868","volume":"25","author":"KR Chaudhuri","year":"2010","unstructured":"Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, Mitra T, Frades-Payo B, Tluk S, et al. The nondeclaration of nonmotor symptoms of Parkinson\u2019s disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord. 2010;25(6):704\u20139. https:\/\/doi.org\/10.1002\/mds.22868.","journal-title":"Mov Disord"},{"issue":"11","key":"246_CR8","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1212\/WNL.0b013e3181d55f24","volume":"74","author":"TA Zesiewicz","year":"2010","unstructured":"Zesiewicz TA, Sullivan KL, Arnulf I, Chaudhuri KR, Morgan JC, Gronseth GS, et al. Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology. 2010;74(11):924\u201331. https:\/\/doi.org\/10.1212\/WNL.0b013e3181d55f24.","journal-title":"Neurology"},{"issue":"3","key":"246_CR9","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1136\/jnnp.69.3.308","volume":"69","author":"A Schrag","year":"2000","unstructured":"Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson\u2019s disease? J Neurol Neurosurg Psychiatry. 2000;69(3):308\u201312.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"246_CR10","unstructured":"Fahn S, Elton R (1987) Members of the UPDRS Development Committee. Unified Parkinson\u2019s Disease Rating Scale. In: Fahn S, Marsden C, Calne D, Goldstein M, editors. Recent Developments in Parkinson\u2019s Disease, Vol 2. Florham Park, NJ: Macmillan Health Care Information. Pp 153\u201363, 293\u2013304."},{"issue":"15","key":"246_CR11","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129\u201370. https:\/\/doi.org\/10.1002\/mds.22340.","journal-title":"Mov Disord"},{"key":"246_CR12","unstructured":"GOCOVRI (amantadine) extended release capsules for oral use (prescribing information) Emeryville, CA. 2017: Adamas Pharma, LLC; 2021. https:\/\/www.gocovrihcp.com\/pdf\/Gocovri_Prescribing_Information.pdf."},{"issue":"1","key":"246_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s40262-018-0663-4","volume":"58","author":"RA Hauser","year":"2019","unstructured":"Hauser RA, Pahwa R, Wargin WA, Souza-Prien CJ, McClure N, Johnson R, et al. Pharmacokinetics of ADS-5102 (amantadine) extended release capsules administered once daily at bedtime for the treatment of dyskinesia. Clin Pharmacokinet. 2019;58(1):77\u201388. https:\/\/doi.org\/10.1007\/s40262-018-0663-4.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"246_CR14","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/mds.27131","volume":"32","author":"W Oertel","year":"2017","unstructured":"Oertel W, Eggert K, Pahwa R, Tanner CM, Hauser RA, Trenkwalder C, et al. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson\u2019s disease (EASE LID 3). Mov Disord. 2017;32(12):1701\u20139. https:\/\/doi.org\/10.1002\/mds.27131.","journal-title":"Mov Disord"},{"issue":"8","key":"246_CR15","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1001\/jamaneurol.2017.0943","volume":"74","author":"R Pahwa","year":"2017","unstructured":"Pahwa R, Tanner CM, Hauser RA, Isaacson SH, Nausieda PA, Truong DD, et al. ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID study): a randomized clinical trial. JAMA Neurol. 2017;74(8):941\u20139. https:\/\/doi.org\/10.1001\/jamaneurol.2017.0943.","journal-title":"JAMA Neurol"},{"issue":"16","key":"246_CR16","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1002\/mds.22341","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Nutt JG, Stebbins GT. The Unified Dyskinesia Rating Scale: presentation and clinimetric profile. Mov Disord. 2008;23(16):2398\u2013403. https:\/\/doi.org\/10.1002\/mds.22341.","journal-title":"Mov Disord"},{"issue":"4","key":"246_CR17","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s40263-018-0498-4","volume":"32","author":"LW Elmer","year":"2018","unstructured":"Elmer LW, Juncos JL, Singer C, Truong DD, Criswell SR, Parashos S, et al. Pooled analyses of phase III studies of ADS-5102 (amantadine) extended-release capsules for dyskinesia in Parkinson\u2019s disease. CNS Drugs. 2018;32(4):387\u201398. https:\/\/doi.org\/10.1007\/s40263-018-0498-4.","journal-title":"CNS Drugs"},{"issue":"2","key":"246_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/00002826-200003000-00003","volume":"23","author":"RA Hauser","year":"2000","unstructured":"Hauser RA, Friedlander J, Zesiewicz TA, Adler CH, Seeberger LC, O\u2019Brien CF, et al. A home diary to assess functional status in patients with Parkinson\u2019s disease with motor fluctuations and dyskinesia. Clin Neuropharmacol. 2000;23(2):75\u201381.","journal-title":"Clin Neuropharmacol"},{"key":"246_CR19","doi-asserted-by":"crossref","unstructured":"Folstein MF, Folstein SE, McHugh PR (1975) \"Mini-mental state\". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 12(3):189\u201398.","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"246_CR20","unstructured":"Movement Disorder Society-Unified Parkinson\u2019s Disease Rating Scale Milwaukee, WI: Movement Disoder Society; 2019 https:\/\/www.movementdisorders.org\/MDS-Files1\/PDFs\/Rating-Scales\/MDS-UPDRS_English_FINAL_February2019.pdf."},{"issue":"5","key":"246_CR21","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/mds.26960","volume":"32","author":"K Horvath","year":"2017","unstructured":"Horvath K, Aschermann Z, Kovacs M, Makkos A, Harmat M, Janszky J, et al. Minimal clinically important differences for the experiences of daily living parts of movement disorder society-sponsored unified Parkinson\u2019s disease rating scale. Mov Disord. 2017;32(5):789\u201393. https:\/\/doi.org\/10.1002\/mds.26960.","journal-title":"Mov Disord"},{"issue":"7","key":"246_CR22","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1136\/jnnp.2005.079053","volume":"77","author":"M Tinazzi","year":"2006","unstructured":"Tinazzi M, Del Vesco C, Fincati E, Ottaviani S, Smania N, Moretto G, et al. Pain and motor complications in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2006;77(7):822\u20135. https:\/\/doi.org\/10.1136\/jnnp.2005.079053.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"246_CR23","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/AJP.0000000000000547","volume":"34","author":"R Aiyer","year":"2018","unstructured":"Aiyer R, Mehta N, Gungor S, Gulati A. A systematic review of NMDA receptor antagonists for treatment of neuropathic pain in clinical practice. Clin J Pain. 2018;34(5):450\u201367. https:\/\/doi.org\/10.1097\/AJP.0000000000000547.","journal-title":"Clin J Pain"},{"issue":"4","key":"246_CR24","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s40263-019-00618-2","volume":"33","author":"D Kreutzwiser","year":"2019","unstructured":"Kreutzwiser D, Tawfic QA. Expanding role of NMDA receptor antagonists in the management of pain. CNS Drugs. 2019;33(4):347\u201374. https:\/\/doi.org\/10.1007\/s40263-019-00618-2.","journal-title":"CNS Drugs"},{"issue":"1","key":"246_CR25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1136\/jnnp-2017-316213","volume":"89","author":"T Simuni","year":"2018","unstructured":"Simuni T, Caspell-Garcia C, Coffey CS, Weintraub D, Mollenhauer B, Lasch S, et al. Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson\u2019s disease: the PPMI cohort. J Neurol Neurosurg Psychiatry. 2018;89(1):78\u201388. https:\/\/doi.org\/10.1136\/jnnp-2017-316213.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"246_CR26","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1111\/ene.14221","volume":"27","author":"D Santos-Garcia","year":"2020","unstructured":"Santos-Garcia D, de Deus Fonticoba T, Suarez Castro E, Aneiros Diaz A, McAfee D, Catalan MJ, et al. Non-motor symptom burden is strongly correlated to motor complications in patients with Parkinson\u2019s disease. Eur J Neurol. 2020;27(7):1210\u201323. https:\/\/doi.org\/10.1111\/ene.14221.","journal-title":"Eur J Neurol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-021-00246-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-021-00246-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-021-00246-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T15:30:16Z","timestamp":1621611016000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-021-00246-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,17]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["246"],"URL":"https:\/\/doi.org\/10.1007\/s40120-021-00246-3","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,17]]},"assertion":[{"value":"30 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}